Danish drugmaker Novo Nordisk is planning to introduce vial presentations of its blockbuster obesity treatment Wegovy (semaglutide), expanding the range of delivery formats available for the therapy as competition intensifies in the weight-management market. The company is exploring multiple vial configurations, with initial launches expected later this year and additional formats to follow.

Wegovy, a GLP-1 receptor agonist used for chronic weight management, is currently available in prefilled injectable pens. By adding vial options, Novo Nordisk aims to offer greater flexibility in dosing and administration for healthcare providers and patients. The move reflects growing demand for varied delivery formats and comes as rivals introduce alternative pricing and packaging strategies to capture market share.

Industry observers view the vial rollout as part of Novo Nordisk’s broader strategy to strengthen its position in the fast-growing obesity drug segment. Vial presentations can support customized dosing and may improve accessibility in certain care settings, helping the company respond to evolving patient needs and competitive pressures.

While Novo Nordisk has not disclosed pricing details or exact launch timelines, the company confirmed that the first vial formats are targeted for release this year, subject to regulatory and manufacturing readiness. The expansion underscores the company’s continued focus on scaling its obesity portfolio and maintaining leadership in one of the pharmaceutical industry’s most dynamic therapeutic areas.